Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG005 + Chemotherapy in Advanced Biliary Tract Carcinoma
NCT07099547Phase 2Recruiting
- Sponsor
- Zelgen
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nilvanstomig in biliary tract carcinoma (BTC), sponsored by Zelgen. Started Dec 2025; status: recruiting.
02
Drugs
nilvanstomig
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT07099547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07099547.